Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 13/20 | 0.80 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.47 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23149143 | 0.95 | ATF4 (0.69) | ATF4RAB9ANPC1TSHR | |
| SCHEMBL23149183 | 0.92 | ATF4 (0.80) | ATF4RAB9ANPC1TSHRNPSR1 | |
| SCHEMBL22656718 | 0.89 | ATF4 (1.00) | ATF4RAB9ANPC1TSHRNPSR1 | |
| SCHEMBL19569281 | 0.84 | ATF4 (0.94) | ATF4RAB9ANPC1TSHRNPSR1 | |
| SCHEMBL19569398 | 0.84 | ATF4 (1.00) | ATF4RAB9ANPC1TSHRNPSR1 | |
| SCHEMBL22614436 | 0.83 | ATF4 (0.86) | ATF4RAB9ANPC1TSHRNPSR1 | |
| SCHEMBL20974142 | 0.81 | ATF4 (1.00) | ATF4RAB9ANPC1TSHRNPSR1 | |
| SCHEMBL23149119 | 0.80 | ATF4 (0.76) | ATF4RAB9ANPC1TSHRNPSR1 | |
| SCHEMBL22397082 | 0.80 | ATF4 (0.80) | ATF4RAB9ANPC1TSHR | |
| SCHEMBL23182921 | 0.79 | MEN1 (0.59) | RAB9ANPC1TSHRNPSR1SENP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-01 | — | — | US | disclosed |
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | ATF4, ATF1, XBP1 | ATF4 1/4885RAB9A 3165/4885NPC1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.